Critical Contrast: Sagimet Biosciences (NASDAQ:SGMT) and Dianthus Therapeutics (NASDAQ:DNTH)

Sagimet Biosciences (NASDAQ:SGMT) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Insider & Institutional Ownership

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Sagimet Biosciences and Dianthus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Earnings and Valuation

This table compares Sagimet Biosciences and Dianthus Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2.00 million	340.02	-$51.04 million	($1.28)	-8.55
Dianthus Therapeutics	$2.04 million	2,896.97	-$162.34 million	($4.15)	-26.05

Sagimet Biosciences has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Sagimet Biosciences and Dianthus Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1	2	7	0	2.60
Dianthus Therapeutics	1	0	13	1	2.93

Sagimet Biosciences presently has a consensus target price of $29.17, suggesting a potential upside of 166.61%. Dianthus Therapeutics has a consensus target price of $126.92, suggesting a potential upside of 17.41%. Given Sagimet Biosciences’ higher probable upside, equities analysts plainly believe Sagimet Biosciences is more favorable than Dianthus Therapeutics.

Volatility and Risk

Sagimet Biosciences has a beta of 3.45, suggesting that its stock price is 245% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.

Summary

Sagimet Biosciences beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.

About Sagimet Biosciences

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.